Rosacea
Conditions
Interventions
Group A:A combination therapy of dot matrix microneedle radiofrequency and Winona recombinant collagen repair liquid dressing
Group B:A combination therapy of dot matrix microneedle radiofrequency and placebo
Sponsors
The First Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Age range is 18-65 years old, with no gender restrictions; (2) Patients diagnosed with rosacea and whose symptoms persist for more than 6 months, according to the 2017 edition of the National Rosacea Expert Committee criteria in the United States, are diagnosed with rosacea (persistent erythema and hypertrophic changes in the middle of the face that may periodically worsen as two diagnostic features of rosacea, meeting one or more criteria, can be diagnosed with rosacea; paroxysmal flushing, papules and/or pustules, telangiectasia, and some ocular manifestations [meibomian telangiectasia, meibomian inflammation, keratitis, conjunctivitis, and corneal scleritis, etc.] are the main features of rosacea, and two or more main features can indicate the diagnosis of rosacea); (3) Willing to comply with the trial requirements and complete the entire trial for a total of 3 months, and able to complete follow-up as required; (4) Voluntarily participate and sign an informed consent form.
Exclusion criteria
Exclusion criteria: (1) Pregnant and lactating women; (2) Individuals with combined photosensitive diseases, autoimmune diseases, or severe organic diseases that affect this study; (3) Those who install pacemakers or internal defibrillators; (4) Individuals with coagulation dysfunction or other systemic diseases; (5) Patients with skin diseases such as damaged, open wounds, purulent wounds, active inflammatory herpes, or malignant tumors or skin tumors of unknown nature within the treatment area; (6) Abnormal mental state or inability to persist in this study; (7) Individuals who have undergone plastic surgery, grinding, laser, injection therapy, or chemical peels on their face within one month; (8) Individuals who are allergic to the test product or have a high sensitivity constitution; (9) Individuals with a history of hypertrophic scars or keloids.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transepidermal Water Loss; | — |
Secondary
| Measure | Time frame |
|---|---|
| Epidermal Water Content;Sebaceous Lipid Content;Erythema Index;Melanin Index;VISIA imaging system analysis; | — |
Countries
China
Contacts
Public ContactYuanyuan Xu
The First Hospital of China Medical University
Outcome results
None listed